Tags

Type your tag names separated by a space and hit enter

Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Int J Cancer 2018; 142(12):2567-2577IJ

Abstract

Hand-foot syndrome (HFS) is the most common adverse effect of capecitabine-containing chemotherapy. The purpose of this study was to assess the efficacies of various prevention and treatment strategies for capecitabine-induced HFS. Searches of the PubMed and Embase databases were performed to identify relevant studies. The risk ratio (RR) with the corresponding 95% confidence interval (CI) was used as an effect measure to evaluate the efficacies of these prevention and treatment strategies. Publication bias was evaluated using Begg's and Egger's tests. Overall and subgroup analyses were conducted. All statistical analyses were conducted with Stata software version 12.0. Seventeen eligible studies were included. Our results indicated that celecoxib was significantly associated with a lower incidence of grade ≥2 capecitabine-induced HFS without heterogeneity (RR = 0.43, 95% CI = 0.23-0.81, I2 = 0.0%). However, pyridoxine and topical urea/lactic acid were not effective toward preventing capecitabine-induced grade 1, 2, 3, ≥1 or ≥2 HFS. Moreover, pyridoxine was not effective in treating capecitabine-induced HFS. Similar results were obtained by subgroup analysis. Our results indicate that celecoxib has potential prophylactic efficacy for capecitabine-induced HFS. However, pyridoxine and topical urea/lactic acid are not associated with a decrease in the incidence of capecitabine-induced HFS.

Authors+Show Affiliations

Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China.The Wenzhou Dental Hospital, 197 Fuqian Street, Lucheng District, Wenzhou City, 325027, People's Republic of China.Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China.Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China.Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China.Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang City, 110001, People's Republic of China.Department of Chemotherapy and Radiotherapy, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Lucheng District, Wenzhou City, 325027, People's Republic of China.

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

29355976

Citation

Huang, Xuan-Zhang, et al. "Clinical Evidence of Prevention Strategies for Capecitabine-induced Hand-foot Syndrome." International Journal of Cancer, vol. 142, no. 12, 2018, pp. 2567-2577.
Huang XZ, Chen Y, Chen WJ, et al. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. Int J Cancer. 2018;142(12):2567-2577.
Huang, X. Z., Chen, Y., Chen, W. J., Zhang, X., Wu, C. C., Wang, Z. N., & Wu, J. (2018). Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. International Journal of Cancer, 142(12), pp. 2567-2577. doi:10.1002/ijc.31269.
Huang XZ, et al. Clinical Evidence of Prevention Strategies for Capecitabine-induced Hand-foot Syndrome. Int J Cancer. 2018 06 15;142(12):2567-2577. PubMed PMID: 29355976.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome. AU - Huang,Xuan-Zhang, AU - Chen,You, AU - Chen,Wen-Jun, AU - Zhang,Xi, AU - Wu,Cong-Cong, AU - Wang,Zhen-Ning, AU - Wu,Jian, Y1 - 2018/02/02/ PY - 2017/09/05/received PY - 2018/01/13/revised PY - 2018/01/16/accepted PY - 2018/1/23/pubmed PY - 2018/12/12/medline PY - 2018/1/23/entrez KW - capecitabine KW - hand-foot syndrome KW - prevention strategies SP - 2567 EP - 2577 JF - International journal of cancer JO - Int. J. Cancer VL - 142 IS - 12 N2 - Hand-foot syndrome (HFS) is the most common adverse effect of capecitabine-containing chemotherapy. The purpose of this study was to assess the efficacies of various prevention and treatment strategies for capecitabine-induced HFS. Searches of the PubMed and Embase databases were performed to identify relevant studies. The risk ratio (RR) with the corresponding 95% confidence interval (CI) was used as an effect measure to evaluate the efficacies of these prevention and treatment strategies. Publication bias was evaluated using Begg's and Egger's tests. Overall and subgroup analyses were conducted. All statistical analyses were conducted with Stata software version 12.0. Seventeen eligible studies were included. Our results indicated that celecoxib was significantly associated with a lower incidence of grade ≥2 capecitabine-induced HFS without heterogeneity (RR = 0.43, 95% CI = 0.23-0.81, I2 = 0.0%). However, pyridoxine and topical urea/lactic acid were not effective toward preventing capecitabine-induced grade 1, 2, 3, ≥1 or ≥2 HFS. Moreover, pyridoxine was not effective in treating capecitabine-induced HFS. Similar results were obtained by subgroup analysis. Our results indicate that celecoxib has potential prophylactic efficacy for capecitabine-induced HFS. However, pyridoxine and topical urea/lactic acid are not associated with a decrease in the incidence of capecitabine-induced HFS. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/29355976/Clinical_evidence_of_prevention_strategies_for_capecitabine_induced_hand_foot_syndrome_ L2 - https://doi.org/10.1002/ijc.31269 DB - PRIME DP - Unbound Medicine ER -